Ge Long Hui A P P·2025-12-30 08:48Core Viewpoint - WuXi AppTec is positioned as a leading integrated CRDMO provider, delivering efficient services to the global pharmaceutical and life sciences industry through continuous internal and external development [1] Group 1: Company Overview - WuXi AppTec offers integrated, end-to-end new drug research and production services [1] - The management team possesses extensive experience in the pharmaceutical industry and has a global perspective [1] - The company is actively launching H-share incentive trust plans to attract and motivate key talent [1] Group 2: Financial Performance - The integrated CRDMO segment is expected to experience a slight revenue decline in 2024, but the performance in the first half of 2025 is anticipated to be strong [1] - The initial coverage of the company has been rated as "Buy" [1]